High throughput, label-free isolation of circulating tumor cell clusters in meshed microwells

Autor: Mert Boya, Tevhide Ozkaya-Ahmadov, Brandi E. Swain, Chia-Heng Chu, Norh Asmare, Ozgun Civelekoglu, Ruxiu Liu, Dohwan Lee, Sherry Tobia, Shweta Biliya, L. DeEtte McDonald, Bassel Nazha, Omer Kucuk, Martin G. Sanda, Benedict B. Benigno, Carlos S. Moreno, Mehmet A. Bilen, John F. McDonald, A. Fatih Sarioglu

Publikováno v: Nature Communications, Vol 13, Iss 1, Pp 1-13 (2022)

Metastatic CTC clusters remain relatively unexplored due to the lack of optimized and practical technologies for their detection. Here the authors report Cluster-Wells to isolate CTC clusters in whole blood; they show this allows viable cluster retri

Externí odkaz: https://doaj.org/article/5012ddfb6f8249cca14a1d80a809d054

Evidence for the importance of post-transcriptional regulatory changes in ovarian cancer progression and the contribution of miRNAs

Autor: Mengnan Zhang, Lilya V. Matyunina, L. DeEtte Walker, Weixuan Chen, Haopeng Xiao, Benedict B. Benigno, Ronghu Wu, John F. McDonald

Publikováno v: Scientific Reports, Vol 7, Iss 1, Pp 1-9 (2017)

Abstract High-throughput technologies have identified significant changes in patterns of mRNA expression over cancer development but the functional significance of these changes often rests upon the assumption that observed changes in levels of mRNA

Externí odkaz: https://doaj.org/article/7897ad282e104afabe0c3c6fd98e370c

Data from Rapid Mass Spectrometric Metabolic Profiling of Blood Sera Detects Ovarian Cancer with High Accuracy

Autor: John F. McDonald, Facundo M. Fernández, Alexander Gray, Benedict B. Benigno, Roman Mezencev, L. DeEtte Walker, Wei Guan, Manshui Zhou

Background: Ovarian cancer diagnosis is problematic because the disease is typically asymptomatic, especially at the early stages of progression and/or recurrence. We report here the integration of a new mass spectrometric technology with a novel sup

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2acdf759f426654c6a9698290f612d37
https://doi.org/10.1158/1055-9965.c.6515089

Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial

Autor: IM Bover Barcelo, Jørn Herrstedt, P. Wang, Dominique Berton-Rigaud, Bobbie J. Rimel, A. du Bois, Sven Mahner, Mansoor Raza Mirza, F.A. de Jong, Elsa Kalbacher, Divya Gupta, Ignace Vergote, Benedict B. Benigno, Anne Dørum, Domenica Lorusso, Paul Bessette, Joseph Buscema, S. Lau, Ursula A. Matulonis, A. Casado Herráez, Jonathan A. Ledermann, Tally Levy

Publikováno v: Mirza, M R, Benigno, B, Dørum, A, Mahner, S, Bessette, P, Barceló, I B, Berton-Rigaud, D, Ledermann, J A, Rimel, B J, Herrstedt, J, Lau, S, du Bois, A, Herráez, A C, Kalbacher, E, Buscema, J, Lorusso, D, Vergote, I, Levy, T, Wang, P, de Jong, F A, Gupta, D & Matulonis, U A 2020, ' Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo : Results from the phase III ENGOT-OV16/NOVA trial ', Gynecologic Oncology, vol. 159, no. 2, pp. 442-448 . https://doi.org/10.1016/j.ygyno.2020.09.006

OBJECTIVE: Niraparib is a poly(ADP-ribose) polymerase (PARP) inhibitor approved for use in heavily pretreated patients and as maintenance treatment in patients with newly-diagnosed or recurrent ovarian cancer following a response to platinum-based ch

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c09e124717329b457b57f0ae200c6650
https://doi.org/10.1016/j.ygyno.2020.09.006

Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer

Autor: Sven Mahner, Mansoor Raza Mirza, Jonathan A. Ledermann, Anna V. Tinker, Y. Li, Nicoletta Colombo, Divya Gupta, Andrés Redondo, Bente Lund, Ursula A. Matulonis, Gabriel Lindahl, Benedict B. Benigno, Frederik Marmé, Antonio González-Martín, Amit M. Oza, Bradley J. Monk, Dominique Berton, Jørn Herrstedt, Jonathan S. Berek

Publikováno v: Matulonis, U, Herrstedt, J, Oza, A, Mahner, S, Redondo, A, Berton, D, Berek, J, Lund, B, Marmé, F, González-Martín, A, Tinker, A, Ledermann, J, Benigno, B, Lindahl, G, Colombo, N, Li, Y, Gupta, D, Monk, B & Mirza, M 2021, ' Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer ', Gynecologic Oncology, vol. 162, no. Suppl. 1, 37, pp. S24-S25 . https://doi.org/10.1016/S0090-8258(21)00693-4
Matulonis, U, Herrstedt, J, Oza, A, Mahner, S, Redondo, A, Berton, D, Berek, J, Lund, B, Marme, F, Gonzalez-Martin, A, Tinker, A, Ledermann, J, Benigno, B, Lindahl, G, Colombo, N, Li, Y, Gupta, D, Monk, B & Mirza, M 2021, ' Long-term safety and secondary efficacy endpoints in the ENGOT-OV16/NOVA phase III trial of niraparib in recurrent ovarian cancer ', Gynecologic Oncology, vol. 162, no. Suppl. 1, pp. S24-S25 . https://doi.org/10.1016/S0090-8258(21)00693-4

Objectives: In the ENGOT-OV16/NOVA study, maintenance therapy with niraparib significantly prolonged progression-free survival (PFS) in patients (pts) with platinum-sensitive recurrent ovarian cancer (PSROC) regardless of germline BRCA mutation (gBRC

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e408f8519c4255ad824add4e1b0e2930
https://doi.org/10.1016/s0090-8258(21)00693-4